Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27919056 | 0.81 | ALDH1A1 (0.41) | CES1ALDH1A1TDP1MAPK1CES2 | |
| SCHEMBL7810264 | 0.80 | CES2 (0.40) | CES1ALDH1A1MAPK1CES2TSHR | |
| SCHEMBL7810262 | 0.80 | CES2 (0.40) | CES1ALDH1A1MAPK1CES2TSHR | |
| SCHEMBL29117952 | 0.79 | CES1 (0.43) | CES1ALDH1A1TDP1MAPK1CES2 | |
| SCHEMBL11043913 | 0.78 | CES1 (0.42) | CES1ALDH1A1CES2NPC1RAB9A | |
| SCHEMBL11043916 | 0.78 | CES1 (0.42) | CES1ALDH1A1CES2NPC1RAB9A | |
| SCHEMBL20919883 | 0.76 | CES1 (0.48) | CES1ALDH1A1TDP1MAPK1CES2 | |
| SCHEMBL28269583 | 0.76 | CES1 (0.48) | CES1ALDH1A1TDP1MAPK1CES2 | |
| SCHEMBL3731523 | 0.76 | CES1 (0.48) | CES1ALDH1A1TDP1MAPK1CES2 | |
| SCHEMBL9575084 | 0.75 | CES1 (0.54) | CES1ALDH1A1TDP1MAPK1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115010753-A | Method for preparing phosphorylated gem-difluorodiene compound in aqueous phase | 南京工业大学 | 2022-09-06 | — | — | CN | disclosed |
| CN-105130726-A | Method for preparing cinnamyl aldehyde compounds | UNIV HUNAN | 2015-12-09 | — | — | CN | disclosed |
| CN-104844422-A | Preparation method of substituted cinnamyl alcohol compound | UNIV DALIAN TECH | 2015-08-19 | — | — | CN | disclosed |
| CN-104592037-A | Synthesis method of cinacalcet | UNIV ZHEJIANG | 2015-05-06 | — | — | CN | disclosed |
| US-20090082362-A1 | Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure | BAKTHAVATCHALAM RAJAGOPAL | 2009-03-26 | — | — | US | disclosed |
| US-6723730-B2 | DIARYL PIPERAZINES AND RELATED COMPOUNDS USEFUL IN THE TREATMENT OF A CHRONIC AND ACUTE PAIN CONDITIONS, ITCH AND URINARY INCONTINENCE. | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082362-A1 | Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure | TRPV1, TRPA1, TRPV5 | CES1 2842/4885ALDH1A1 1282/4885TDP1 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.